Irbesartan cost-effective treatment of diabetic kidney disease in patients with type 2 diabetes

November 18, 2002

CHICAGO, November 17, 2002 - Up to $2.3 billion in total health care cost savings could be achieved in just three years if Americans with type 2 diabetes and kidney disease received treatment with irbesartan, according to an economic analysis of the international Irbesartan Diabetic Nephropathy Trial (IDNT) presented today in Chicago.

"If patients with type 2 diabetes and kidney disease were treated with the angiotensin II receptor blocker irbesartan we could prevent, in the U.S. alone, about 35,000 cases of end-stage kidney disease at a cost savings of up to $2.3 billion over three years," said Edmund J. Lewis, M.D., director of nephrology at Rush-Presbyterian-St. Luke's Medical Center, Chicago and lead investigator of IDNT. "From a health economic perspective this is obviously good news. More importantly, though, irbesartan provides patients with the best standard of care and may, over time, extend their lives by seven to nine months."

The projected long-term economic benefits of irbesartan treatment relate to the drug's ability to slow the progression of late stage kidney disease or kidney failure in patients with type 2 diabetes. In the IDNT study, irbesartan reduced the risk of doubling of the serum (blood) creatinine or end-stage renal disease by 33 percent (p=0.003) versus placebo, and by 37 percent (p<0.001) versus amlodopine (a calcium channel blocker). The IDNT study also demonstrated that irbesartan significantly reduced the risk of progression of kidney disease or death by 23 percent compared to those treated with amlodipine (p=0.006) and by 20 percent compared to those receiving a placebo (p=0.02). This means that even patients taking irbesartan, who progressed to kidney failure, progressed more slowly, on average taking one year longer before needing dialysis.

From a health economic perspective, irbesartan use among patients with type 2 diabetes and kidney disease may potentially result in approximate gains of seven to nine months of life at a health care cost savings per patient of $13,000 to $23,000 after 25 years. When extrapolated to the estimated U.S. population of such patients, the potential net savings could reach between $7 and $13 billion dollars. Irbesartan may also help prevent the need for dialysis or kidney transplantation, which currently costs approximately $50,000 per U.S. patient annually. Without dialysis or transplantation, nearly 70,000 Americans would die from kidney disease each year.

The American Diabetes Association (ADA), taking into account the results of clinical trials such as IDNT, issued guidelines in January 2002 that recommend angiotensin II receptor blockers, such as irbesartan, as the agent of choice in the treatment of patients with type 2 diabetes and evidence of kidney disease. The U.S. Food and Drug Administration approved the use of irbesartan for the treatment of diabetic nephropathy in September 2002.

Earlier this year (June) the European Commission also approved the use of irbesartan for the treatment of both early and late stage diabetic renal disease in hypertensive type 2 diabetic patients. IDNT cost effectiveness models, developed using country-specific costs from France and Belgium, also showed that irbesartan led to improved life expectancy and total lifetime cost savings. Costs saved ranged from approximately Euro 12,000 per patient ($12,000) to Euro 23,000 ($23,000) per patient depending on the country and comparator.

"Whether the analyses were conducted in the U.S. or Europe, they show that treating eligible patients, early, with irbesartan equates to financial savings and increased life expectancy for patients," said Roger Rodby, M.D., associate professor, Section of Nephrology at Rush-Presbyterian-St. Luke's Medical Center, Chicago.

Hypertension affects more than 600 million people worldwide and hypertension-associated diseases such as cardiovascular disease and diabetic kidney disease are the leading cause of death in the developed world. Patients with type 2 diabetes have nearly a 50 percent risk of having diabetic kidney disease, which is associated with an almost inevitable progression to kidney failure. About 12.5 million Americans suffer from chronic kidney failure and more than 424,000 have developed end-stage kidney disease (End Stage Renal Disease or ESRD). Men, the elderly and members of the Native American, African American and Asian/Pacific Islander population groups are at greatest risk of developing ESRD.
-end-
This event is not part of the official Scientific Sessions 2002 as planned by the American Heart Association Committee on Scientific Sessions Program.

IDNT was supported by an educational grant from Bristol-Myers Squibb and Sanofi-Synthelabo.

Contacts:
Mary Ann Schultz
Rush-Presbyterian-St. Luke's Medical Center
312-942-7816

Sarah Swift
Porter Novelli
917-650-3849

Porter Novelli

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.